Tors. Nat Med 2003, 9(six):66976. 39. Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in mixture with cytotoxic therapy in preclinical research. Cancer Res 2005, 65(three):67180. 40. Kim SE, Shim KN, Jung SA, Yoo K, Lee JH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial development issue in gastric cancer. Gut Liver 2009, 3(2):884. 41. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth aspect expression in gastric carcinoma. Cancer 1996, 77(5):85863. 42. Song ZJ, Gong P, Wu YE: Connection between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. Globe J Gastroenterol 2002, 8(four):59195. 43. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in sufferers with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24(33):5201206. 44. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP: Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in individuals with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29(7):86874. 45. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, et al: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010, 21(ten):1999004. 46. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al: Bevacizumab in combination with chemotherapy as first-line therapy in sophisticated gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29(30):3968976. 47. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, et al: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a completely human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial development element receptor-2.Escitalopram J Clin Oncol 2010, 28(5):78087.PLP (139-151) 48.PMID:23892746 Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al: REGARD: A phase III, randomized, double-blinded trial of ramucirumab and very best supportive care (BSC) versus placebo and BSC in the therapy of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following illness progression on first-line platinum- and/or fluoropyrimidine-containing mixture therapy [abstract]. J Clin Oncol 2012(suppl 34):LBA5. http://www.asco.org/. 49. Tian S, Quan H, Xie C, Guo H, LF, Xu Y, Li J, Lou L: YN968D1 is really a novel and selective inhibitor of vascular endothelial development element receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011, 102(7):1374380.Qiu and Xu Biomarker Investigation 2013, 1:32 http://www.biomarkerres.org/content/1/1/Page eight of50. Li J, Qin S, Xu J, Guo WJ, Xiong JP, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: A randomized, double-blind, multicenter, phase, three-arm, placebo-control study of apatinib as third-line remedy in individuals with metastatic gastric carcinoma [abstract]. J Clin Oncol 2011, 29(Suppl):4019. 51. Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR: Aflibercept:.